Letter

Rosiglitazone and heart deaths

Glycaemic control is a myth

BMJ 2007; 334 doi: 10.1136/bmj.39234.451296.3A (Published 14 June 2007)
Cite this as: BMJ 2007;334:1236.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Illtyd R Thomas, general practitioner
  1. Swansea SA1 5LF
  1. illtyd.thomas{at}gp-w98027.wales.nhs.uk

    Tight control of HbA1c levels has been enshrined in the QOF (quality and outcomes framework) of the new general practitioner contract as being an evidence based proposal. Multiple drugs are licensed on the understanding that they reduce HbA1c levels and that this is a good thing. So should …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular